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Abstract 
Background: The CYP2C19 nonfunctional genotype reduces clopidogrel effectiveness after percutaneous coro-
nary intervention (PCI). Following clinical implementation of CYP2C19 genotyping at University Florida (UF) Health 
Shands Hospital in 2012, where genotype results are available approximately 3 days after PCI, testing was expanded 
to UF Health Jacksonville in 2016 utilizing a rapid genotyping approach. We describe metrics with this latter 
implementation.
Methods: Patients at UF Health Jacksonville undergoing left heart catheterization with intent to undergo PCI were 
targeted for genotyping using the Spartan RX™ system. Testing metrics and provider acceptance of testing and 
response to genotype results were examined, as was antiplatelet therapy over the 6 months following genotyping.
Results: In the first year, 931 patients, including 392/505 (78%) total patients undergoing PCI, were genotyped. The 
median genotype test turnaround time was 96 min. Genotype results were available for 388 (99%) PCI patients prior 
to discharge. Of 336 genotyped PCI patients alive at discharge and not enrolled in an antiplatelet therapy trial, 1/6 
(17%) poor metabolizers (PMs, with two nonfunctional alleles), 38/93 (41%) intermediate metabolizers (IMs, with 
one nonfunctional allele), and 119/237 (50%) patients without a nonfunctional allele were prescribed clopidogrel 
(p = 0.110). Clopidogrel use was higher among non-ACS versus ACS patients (78.6% vs. 42.2%, p < 0.001). Six months 
later, among patients with follow-up data, clopidogrel was prescribed in 0/4 (0%) PMs, 33/65 (51%) IMs, and 115/182 
(63%) patients without a nonfunctional allele (p = 0.008 across groups; p = 0.020 for PMs versus those without a non-
functional allele).
Conclusion: These data demonstrate that rapid genotyping is clinically feasible at a high volume cardiac catheteriza-
tion facility and allows informed chronic antiplatelet prescribing, with lower clopidogrel use in PMs at 6 months.
Trial registration ClinicalTrials.gov Identifier: NCT02724319; registered March 31, 2016; https ://www.clini caltr ials.gov/
ct2/show/NCT02 72431 9?term=angio lillo &rank=7
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Background
Dual antiplatelet therapy with aspirin and a  P2Y12 
receptor inhibitor is the standard of care for patients 
with coronary artery disease (CAD) undergoing percu-
taneous coronary intervention (PCI) [1, 2]. Currently, 
three oral  P2Y12 receptor antagonists (clopidogrel, 
prasugrel, and ticagrelor) are clinically available. Clopi-
dogrel remains broadly utilized, which may be attrib-
uted to its lower cost, given that it is available in a 
generic formulation, and its expanded indications com-
pared with prasugrel and ticagrelor [3, 4]. Prasugrel and 
ticagrelor in fact have an indication only for the treat-
ment of patients with acute coronary syndrome (ACS), 
while clopidogrel is the only oral  P2Y12 receptor antag-
onist also with an indication for the treatment of stable 
CAD [5]. Compared to clopidogrel, prasugrel and tica-
grelor lead to a greater reduction in atherothrombotic 
events, albeit at the expense of increased bleeding not 
related to coronary artery bypass grafting, but clopi-
dogrel is still frequently used [3, 4, 6].
Clopidogrel is a thienopyridine that requires bioacti-
vation to an active metabolite that irreversibly binds the 
platelet  P2Y12 receptor and inhibits platelet activation 
and subsequent aggregation [3, 5]. There is significant 
inter-patient variability in clopidogrel-induced anti-
platelet effects, which has important prognostic impli-
cations [7, 8]. In particular, in patients undergoing PCI, 
studies have consistently shown that those with reduced 
clopidogrel-induced antiplatelet effects, who thus persist 
with high on-clopidogrel platelet reactivity, are at high 
risk for ischemic recurrences, including stent thrombo-
sis [8–11]. Emerging studies have also shown that the 
presence of enhanced clopidogrel-induced antiplatelet 
effects, leading to low platelet reactivity, may increase 
the risk of bleeding complications [9]. Multiple factors, 
including clinical, cellular, and genetic factors, may con-
tribute to interindividual response variability to clopi-
dogrel [7]. Among the genetic factors, polymorphisms in 
the CYP2C19 gene have consistently shown to have a role 
[12–14].
The CYP2C19 enzyme is involved in both metabolic 
steps mediating the biotransformation of clopidogrel to 
its pharmacologically active form. The CYP2C19*2 and *3 
alleles are referred to as nonfunctional alleles and confer 
absent enzyme activity. These alleles are associated with 
lower plasma concentrations of the active metabolite and 
reduced platelet inhibition with clopidogrel [15]. Stud-
ies conducted in clopidogrel-treated patients undergoing 
PCI have shown an increased risk for ischemic events, 
in particular stent thrombosis, in the presence of a non-
functional allele [12, 16]. Prasugrel and ticagrelor are 
newer  P2Y12 receptor inhibitors that are not affected 
by the CYP2C19 genotype [17, 18], and consortium 
guidelines recommend consideration of these agents in 
patients with a nonfunctional genotype [14].
In June 2012, CYP2C19 testing on a GenMark  Dx® 
platform (GenMark Diagnostics, Inc., Carlsbad, CA) 
was launched at the University of Florida (UF) Health 
Shands Hospital in Gainesville to assist with selec-
tion of antiplatelet therapy after PCI, and metrics with 
this implementation have been described [19]. This 
was a pharmacist-led effort. In April 2016, in a physi-
cian-led effort, CYP2C19 testing was launched at UF 
Health Jacksonville, whereby patients undergoing left 
heart catheterization with intent to undergo PCI were 
genotyped on a Spartan RX™ platform (Spartan Biosci-
ence Inc, Ottawa, ON). This provided experience with a 
rapid genotyping approach to clinical CYP2C19 testing. 
Herein we describe implementation metrics associated 
with CYP2C19 genotype-guided antiplatelet therapy at 
UF Health Jacksonville. We specifically report on physi-
cian uptake of CYP2C19 testing, genotype results and 
turnaround time, and both acute and chronic antiplatelet 
therapy prescribed after genotype results were available. 
We also describe lessons learned based on our experi-




Patients undergoing emergent or planned left heart cath-
eterization with intent to undergo PCI were targeted for 
testing. Patients with a history of human immunodefi-
ciency virus or hepatitis C virus were excluded. Writ-
ten informed consent for clinical CYP2C19 testing and 
collection of clinical data and a blood sample for future 
research were obtained from each patient. Genetic sam-
ples were collected via a buccal swab prior to cardiac 
catheterization when possible. For patients undergoing 
emergency procedures (e.g., ST-segment elevation myo-
cardial infarction) or otherwise unable to provide consent 
prior to catheterization (e.g., patients with cardiogenic 
shock or intubated), informed consent and genetic sam-
pling were obtained following PCI after patients were sta-
bilized. Patients not receiving PCI were not tested after 
diagnostic left heart catheterization.
Genetic samples were transported to the college of 
American pathologist/CLIA licensed pathology labora-
tory, located five floors below the cardiac catheterization 
laboratory. Samples were processed using the Spartan 
RX™ system, which tests for the CYP2C19 nonfunctional 
*2 (c.681G>A; rs4244285) and *3 (c.636G>A; rs4986893) 
alleles and the increased function *17 (c.-806C>T; 
rs12248560) allele [20]. Those lacking a *2, *3, or *17 allele 
were assigned the *1 allele designation. Phenotypes were 
assigned according to standardized nomenclature, with 
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PMs having two nonfunctional alleles (e.g. *2/*2), IMs 
having a single nonfunctional allele (e.g. *1/*2, *2/*17), 
normal metabolizers (NMs) having the *1/*1 genotype, 
and rapid and ultra-rapid metabolizers (RMs and UMs) 
having the *1/*17 and *17/*17 genotypes, respectively 
[21]. One Spartan RX™ system was initially available, 
but a second system was added in May 2017 to accom-
modate testing multiple patients at once. In the event of 
inconclusive genotype results, collection of an additional 
buccal cell sample for genotyping was attempted. Testing 
was only available Monday through Friday. For patients 
presenting on the weekend for emergency PCI, samples 
were collected on Monday for genotyping if the patient 
remained hospitalized.
The overall goal was to have genetic information avail-
able by the end of the PCI procedure or before discharge 
for patients unable to provide informed consent prior to 
coronary intervention. Genotype and phenotype results 
were placed in the Epic electronic health record (EHR) 
under the laboratory reports tab, with phenotype assign-
ment as described above. Results were communicated to 
physicians via an inbox message to use at their discre-
tion taking into consideration other factors (e.g., clinical 
presentation, cardiovascular risk factors, concomitant 
medications, insurance, PCI complexity) in making anti-
platelet therapy decisions. No clinical pharmacist support 
was provided. Genotyping kits and systems were donated 
by Spartan Biosciences, Inc. Technical and pathologist 
time was paid through grant support.
Data collection and analysis
Data for the first 12  months of implementation were 
collected on the genotype test ordering rate, genotype 
turnaround time (defined as the time between the sample 
arrival in the pathology laboratory to the time the report 
was signed by the pathologist) and genotype results. For 
patients receiving PCI, data were also collected on anti-
platelet therapy at discharge and 6 months after coronary 
intervention. Metrics data were tracked through review 
of patient encounters in the EHR and telephone calls. 
Use of clopidogrel was compared between PMs, IMs, and 
patients without a nonfunctional allele (e.g., combination 
of NMs, RMs, and UMs) using Chi square analysis or the 
Fisher’s exact test. Changes in antiplatelet therapy from 
baseline to 6  months were assessed within each pheno-
type group using the McNemar test. All analyses were 
conducted using SAS version 9.4 (SAS, Cary, NC). Study 
procedures and data collection were approved by the 
Institutional Review Board at UF Health Jacksonville, and 
all procedures were in accordance with the ethical stand-
ards of the Declaration of Helsinki.
Results
From April 28, 2016 to April 27, 2017, 931 patients under-
going left heart catheterization for suspected coronary 
disease were genotyped, representing 68% (931/1366) 
of all patients undergoing left heart catheterization dur-
ing that period (Table  1). The median genotype test 
turnaround time was 96 (interquartile range of 78–144) 
min. Genotyping for 129 patients (14%) was unsuccess-
ful with the initial sample (56 inconclusive results, 73 
device errors). One additional sample was collected in 
113 patients, two additional samples were collected in 10 
patients, and 6 patients refused sample recollection. Nine 
of the 123 patients with additional sample collection had 
multiple inconclusive results.
A total of 392 of the 931 genotyped patients (42%) 
underwent PCI, representing 78% (392/505) of all 
patients undergoing PCI during the 12  month period. 
Of these, 4 (1%) had inconclusive genotype results. Of 
the 113 patients receiving PCI and not genotyped, 12 
refused to participate in the study and the remaining 101 
were excluded, unable to provide informed consent, or 
not approached about testing (e.g. underwent PCI over 
the weekend and were discharged before they could be 
consented). The characteristics of the genotyped patients 
Table 1 CYP2C19 test ordering and adoption rates in the first 12 months at UF Health Jacksonville
PCI percutaneous coronary intervention
Implementation metric No. of patients (%)
Total number of patients who underwent left heart catheterization 1366
 Patients who were genotyped 931
 Genotype test adoption rate 931/1366 (68%)
  Genotypes successfully completed with initial sample 802 (86%)
Total number of patients who underwent PCI 505
 PCI patients who were genotyped 392
 Genotype test adoption rate 392/505 (78%)
  Patients included in the analysis of antiplatelet therapy at discharge 336
  Patients included in the analysis of antiplatelet therapy at 6 months 258
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receiving PCI are shown in Table  2. The majority were 
male and presented with an ACS at the time of PCI. 
Twenty-nine percent had a *2 allele; 27% were interme-
diate metabolizers (IMs) and 2% were poor metabolizers 
(PMs). The *3 allele was not detected in any patient.
Fifty-one patients (14 with a *2 allele and 37 without 
a *2 allele) were enrolled in the Ticagrelor With Aspirin 
or Alone in High-Risk Patients After Coronary Inter-
vention (TWILIGHT) trial (ClinicalTrials.gov Identifier: 
NCT02270242), which dictated treatment with ticagrelor 
for 3  months following PCI [22]. An additional patient 
died prior to hospital discharge. After excluding these 
52 patients, plus 4 patients with inconclusive genotype 
results, 1 of 6 (17%) PMs, 38 of 93 (41%) IMs, and 119 
of 237 patients without a *2 allele (50%) were placed on 
clopidogrel at the time of discharge (p = 0.110 for com-
parison across groups; Fig.  1). The remaining 178/336 
patients were treated with prasugrel (81/178, 45.5%) or 
ticagrelor (97/178, 54.5%).
At the time of data collection for the present analy-
sis, 6  month post-PCI follow-up data were available for 
258 patients. Of 251 still taking a  P2Y12 inhibitor, use of 
clopidogrel increased significantly in IMs (p = 0.002) and 
patients without a *2 allele (p < 0.001) from discharge to 
6  months, but remained low in PMs. At 6  months, 0/4 
(0%) PMs, 33/65 (51%) IMs, and 115/182 (63%) patients 
without a *2 allele were prescribed clopidogrel (p = 0.008 
for comparison across groups). Clopidogrel use was sig-
nificantly higher in those without a *2 allele compared to 
PMs (p = 0.020), but not compared to IMs (p = 0.104).
When stratifying antiplatelet therapy by PCI indica-
tion, there was significantly higher use of clopidogrel 
in non-ACS patients (n = 28) versus ACS patients 
(n = 223) at discharge (78.6% vs. 42.2%, p < 0.001) and 
6 months (82.1% vs. 56.1%, p = 0.008). Similar to data in 
the whole population, among ACS patients, clopidogrel 
use increased significantly from baseline to 6 months in 
patients without a CYP2C19*2 allele (45.6% at discharge 
to 58.9% at 6 months, p < 0.001), as well as in IMs (35.5% 
at discharge to 51.6% at 6  months, p = 0.004), whereas 
all PMs received alternative therapy at discharge and 
6  months. There were too few non-ACS patients for 
analysis of changes in antiplatelet therapy over time by 
genotype.
Lessons learned
The implementation at UF Health Shands Hospital in 
Gainesville has been previously described [19]. Table  3 
compares implementation approaches between UF 
Health Jacksonville and UF Health Shands Hospital in 
Gainesville and lessons learned based on experience 
with the two approaches. A major challenge with the 
genotyping approach in Gainesville was that the delay in 
obtaining genotype results significantly disrupted pro-
vider workflow given the need to follow up on results 
returned 3–4  days after the PCI procedure, which was 
often after the patient had been discharged. An effective 
communication strategy utilizing both clinical pharma-
cist support and electronic clinical decision support was 
Table 2 Characteristics of patients who underwent PCI 
and CYP2C19 genotyping over the first 12 months
Mean ± SD or no. (%)
PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial 
infarction, NSTEMI non-ST-segment elevation myocardial infarction, TIA transient 
ischemic attack
a Warfarin, direct oral anticoagulant, or low molecular weight heparin
Characteristic n = 392
Age (years) 63 ± 11
Male sex 271 (69)
Race
 White 292 (74.5)
 Black 93 (23.7)
 Asian 3 (0.8)
 Other or not reported 4 (1.0)
Past medical history
 Stroke or TIA 48 (12.2)
 Gastrointestinal hemorrhage 7 (1.8)
 Intracranial hemorrhage 2 (0.5)
PCI indication
 STEMI 74 (18.9)
 NSTEMI 99 (25.2)
 Unstable angina 174 (44.4)
 Stable coronary disease 45 (11.5)
P2Y12 inhibitor on admission
 Clopidogrel 99 (25.3)
 Prasugrel 9 (2.3)
 Ticagrelor 13 (3.3)
 Other or not available 11 (2.8)
Anticoagulant on  admissiona
 Warfarin 9 (2.3)
 Direct oral anticoagulant 12 (3.0)
 Low molecular weight heparin 1 (0.3)
 Not available 9 (2.3)
Anticoagulant at  dischargea
 Warfarin 16 (4.1)
 Direct oral anticoagulant 16 (4.1)
 Low molecular weight heparin 1 (0.3)
CYP2C19 phenotype
 Poor metabolizer (*2/*2) 7 (1.8)
 Intermediate metabolizer (*1/*2, *2/*17) 106 (27.0)
 Normal metabolizer (*1/*1) 145 (37.0)
 Rapid metabolizer (*1/*17) 110 (28.1)
 Ultra-rapid metabolizer (*17/*17) 20 (5.1)
 Inconclusive 4 (1.0)
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necessary in this setting to alert providers about patients 
with a nonfunctional allele so that appropriate antiplate-
let therapy could be instituted. This approach was suc-
cessful in ensuring high uptake of prasugrel or ticagrelor 
in both PMs and IMs, whereas most patients without a 
nonfunctional allele were treated with clopidogrel. In 
contrast, neither pharmacist support nor clinical deci-
sion support were used to assist with antiplatelet therapy 
in Jacksonville where results are usually available 1–2  h 
after sample collection, and well before patient discharge. 
Also in contrast to UF Health, Gainesville, prasugrel or 
ticagrelor was commonly prescribed in the acute post-
PCI phase at UF Health, Jacksonville regardless of geno-
type. Genotype was available to inform switches after 
the acute phase from more potent and expensive  P2Y12 
inhibitors to clopidogrel in patients without a nonfunc-
tional allele, as evidenced by significantly increased use of 
clopidogrel in those without a *2 over the initial 6 month 
period and continued use of prasugrel or ticagrelor in 
PMs. Interestingly, use of clopidogrel in IMs increased 
over time at UF Health, Jacksonville, which is against 
guideline recommendations. Thus, an important lessons 
learned is that some sort of clinical decision support is 
needed to assist with genotype-guided chronic antiplate-
let therapy decisions. Another lesson learned was that 
genotyping was useful in informing antiplatelet therapy 
in the setting where clopidogrel was the preferred anti-
platelet agent (at UF Health, Gainesville) and in the set-
ting where more potent  P2Y12 inhibitors were preferred 
early after PCI (at UF Health, Jacksonville), with a switch 
to clopidogrel after the acute period, assuming that clini-
cal decision support can be put in place to ensure appro-
priate genotype-guided clopidogrel use.
Discussion
We previously showed that CYP2C19 testing in conjunc-
tion with clinical decision support and clinical phar-
macist participation can be successfully integrated into 
clinical care to guide antiplatelet therapy after PCI, with 
high prescriber adoption rates of the testing and rec-
ommendations for alternative therapy for patients with 
a nonfunctional allele during the initial year of the pro-
gram [19]. Herein, we extend those findings based on 
a physician-led implementation at another UF Health 
institution. While there were some research aspects to 
the implementation, including obtaining consent for 
sample storage for future research, most aspects of the 
implementation were done as part of clinical care, with 
genotyping performed in a CAP/CLIA-licensed labora-
tory, results placed in the EHR, and prescribing decisions 
left to the provider. Other institutions across the United 
States have also clinically implemented CYP2C19 testing 
to guide post-PCI antiplatelet therapy, with a description 
of strategies undertaken recently published [23]. Con-
sistent with a recent publication from the University of 
Alabama, Birmingham [24], we show that, in the largest 
single institution study reported to date, use of a rapid 
CYP2C19 genotyping platform outside of a clinical trial 
is clinically feasible. We further show that the availabil-
ity of a rapid and user-friendly genotyping platform led to 
high adoption of CYP2C19 testing for patients presenting 
to the cardiac catheterization laboratory with intent for 
PCI.
Clopidogrel reduces the risk for adverse cardiovascu-
lar events after an ACS, and additional data show reduc-
tions in the risk for cardiovascular events, including stent 
thrombosis, with clopidogrel use after PCI [1, 5, 6]. How-
ever, the CYP2C19 nonfunctional genotype compromises 
the efficacy of clopidogrel, leading to reduced formation 
of the active thiol metabolite and reduced inhibition of 
platelet aggregation [15]. While the impact of CYP2C19 
genotype on clopidogrel efficacy in lower risk populations 
who do not undergo PCI is questionable [25, 26], the data 
consistently show reduced clopidogrel effectiveness after 
PCI in carriers of a nonfunctional allele, with the lowest 
effectiveness observed in PMs [12, 16]. Based on these 
data, guidelines by the Clinical Pharmacogenetics Imple-
mentation Consortium (CPIC) recommend integrating 
available genotype results into prescribing decisions for 
antiplatelet therapy after PCI [14]. They specifically rec-
ommend prasugrel or ticagrelor for patients with a LOF 
allele in the absence of contraindications.
While CPIC guidelines do not provide recommen-
dations on whether or not to order genotyping, leaving 
that to the discretion of the physician, this is addressed 
in practice guidelines for the management of patients 
undergoing PCI [1, 2]. These guidelines recommend 
Fig. 1 Percent of patients on clopidogrel at discharge and 6 months 
by CYP2C19 phenotype. PM poor metabolizer, IM intermediate 
metabolizer. Other includes normal metabolizers, rapid metabolizers, 
and ultra-rapid metabolizers. *p = 0.020 for PM versus other at 
6 months. **p = 0.104 for IM versus other at 6 months
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against routine use of genetic testing for all patients 
undergoing PCI, citing an absence of data from large 
randomized controlled trials, but state that testing may 
be considered for patients at high risk for poor out-
comes. Two multi-center trials assessing the efficacy 
of genotype-guided antiplatelet prescribing after PCI 
are ongoing but are not expected to be completed for at 
least a year (ClinicalTrials.gov Identifiers: NCT01742117 
and NCT01761786). There are, however, recent data 
on outcomes from a pragmatic clinical trial showing a 
reduced risk of the composite of ischemic and bleeding 
events with genotype-guided antiplatelet therapy versus 
usual care in patients with ACS, most of whom under-
went PCI [27]. There are additional data from pragmatic 
studies of CYP2C19 genotyping in clinical care. Specifi-
cally, we showed in a study of 412 patients who under-
went CYP2C19 genotyping and PCI at UF Health in 
Gainesville that there was a higher incidence of major 
adverse cardiovascular events (MACE), consisting of 
cardiovascular death, myocardial infarction, stroke, or 
stent thrombosis, in patients with a nonfunctional allele 
treated with clopidogrel versus prasugrel or ticagrelor 
[28]. In a subsequent study of 1815 patients genotyped 
across seven medical centers, we observed an increased 
risk for MACE, defined as death from any cause, non-
fatal myocardial infarction, or non-fatal stroke, in non-
functional allele carriers treated with clopidogrel versus 
alternative therapy (adjusted hazard ratio of 2.26, 95% 
confidence interval 1.18–4.32) [29]. There remained sig-
nificantly worse outcomes with clopidogrel compared 
to alternative therapy when limiting the analysis to IMs. 
This is noteworthy because the FDA-approved clopi-
dogrel labeling includes a boxed warning about reduced 
drug effectiveness in PMs, with two nonfunctional alleles, 
but does not address IMs, with a single nonfunctional 
allele [30]. A cost-effectiveness analysis based on event 
rates in this study is underway. Previous cost-effective-
ness analyses using event rate probabilities derived from 
clinical trials or cohort studies showed that a genotype-
guided approach to antiplatelet therapy after ACS and 
PCI is cost effective compared to universal clopidogrel, 
ticagrelor, or prasugrel [31, 32].
There were a number of valuable lessons learned based 
on our experience implementing CYP2C19 testing at two 
different hospitals within UF Health. First, a number of 
conditions must be met for rapid genotyping to be fea-
sible in the clinical setting. A genetic test is considered 
a high complexity test according to the Clinical Labora-
tory Improvement Amendments (CLIA) and must be 
performed according to a college of American patholo-
gist/CLIA accredited process in the US [33]. Thus, while 
rapid genotyping platforms may be designed as point-
of-care tests outside the US, they cannot be used in this 
manner in the US in the absence of a licensed molecu-
lar medical technologist available to perform the test. 
This generally requires the platform to be placed in the 
CAP/CLIA certified pathology laboratory, as done at UF 
Health Jacksonville. Relative to the Spartan RX™ sys-
tem, the only FDA-cleared platform for rapid CYP2C19 
genotyping, the genetic sample must be placed in the 
instrument within an hour of collection, necessitating 
dedicated staff to efficiently deliver the sample to the 
pathology laboratory. While this process works well at 
UF Health Jacksonville given the close proximity of the 
cardiac catheterization and clinical pathology labora-
tories, it is not feasible at UF Health Shands Gainesville 
where the pathology laboratory is located farther away. 
Another limitation of the Spartan RX™ system is that 
only a single sample can be genotyped at a time. Thus, 
to increase genotyping capacity at the Jacksonville site, a 
second system was added. However, this still limited the 
number of patients we could genotype and contributed to 
our inability to offer genotyping to all patients undergo-
ing left heart catheterization. Finally, 13.9% of samples 
initially failed to genotype with the Spartan RX™ system, 
requiring repeat sample collection and increasing the 
cost of testing.
The approach taken at UF Health Jacksonville was to 
genotype all patients undergoing left heart catheteriza-
tion with intent for PCI. While 58% of patients did not 
immediately proceed to PCI, in the event that patients 
return for PCI in the future, genotype will be readily 
available in the EHR to help inform therapy. The avail-
ability of a rapid genotyping platform, however, negates 
the need to genotype all patients at the time of cardiac 
catheterization and allows for efficient genotyping at the 
time of PCI.
Another important lesson is that when genotype results 
are not available for several days after PCI, as was the 
case at UF Health Gainesville, it creates significant dis-
ruptions in workflow caused by the need to adjust ther-
apy after the patient has left the cardiac catheterization 
laboratory and potentially after the patient has been dis-
charged from the hospital. In fact, this was the primary 
barrier cited by two large private practices in Florida with 
high volume cardiac catheterization laboratories, who we 
previously approached about implementing CYP2C19 
testing. This suggests that to implement testing more 
broadly, genotyping should cause minimal to no negative 
impact on work flow. Solutions to this problem are either 
preemptive pharmacogenetic testing, so that results are 
available ahead of PCI, or rapid genotyping at the time of 
PCI as done at UF Health Jacksonville. In the landscape 
of a lack of reimbursement for preemptive pharmacoge-
netic testing, the use of rapid genotyping platforms may 
be the most feasible solution at this time.
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A third lesson learned was that despite the shift to 
newer agents early after ACS and PCI, genotype still has 
an important role in informing on the choice of long-
term antiplatelet therapy and specifically with inform-
ing de-escalation from more potent antiplatelet therapy 
early after PCI to clopidogrel for maintenance therapy. 
This has important prognostic implications given that 
most ischemic events occur early (i.e., first month), while 
bleeding events continue to accrue over time particularly 
with the long-term use of prasugrel and ticagrelor [34, 
35]. These observations have led to experts to advocate 
that the use of prasugrel or ticagrelor be limited to the 
first few weeks or month after PCI to reduce the risk of 
ischemic events, and then therapy de-escalated to clopi-
dogrel to minimize the risk of bleeding complications 
[3, 36]. However, a non-guided de-escalation approach 
(e.g. without genotyping or platelet function testing) to 
a less potent agent has been associated with conflicting 
outcomes findings [37, 38], with very early de-escalation 
after an ACS event associated with an increased risk of 
ischemic events. On the contrary, the recently reported 
testing responsiveness to platelet inhibition on chronic 
antiplatelet treatment for acute coronary syndromes 
(TROPICAL-ACS) trial, using a platelet function guided 
approach, provides a justification for a de-escalation 
strategy [39]. The trial specifically demonstrated that 
de-escalation from prasugrel to clopidogrel, guided by 
platelet function testing, was non-inferior to continued 
prasugrel use in preventing adverse cardiovascular events 
after ACS and PCI. A limitation with platelet function 
testing is that it must be performed while the patient is 
on treatment. That is, patients in the TROPICAL-ACS 
trial were switched to clopidogrel for 1 week prior to test-
ing, and only those with sufficient evidence of platelet 
inhibition were continued on clopidogrel, whereas those 
with high on-treatment platelet reactivity were switched 
back to prasugrel. A strategy of de-escalation and escala-
tion back to prasugrel or ticagrelor with repeated meas-
ures of platelet function may not always be practical and 
can be inconvenient for the patient [40]. Genotyping may 
represent another means of guiding de-escalation, and 
unlike platelet function testing, it can be done apriori, 
without the need to switch the patient to clopidogrel 
prior to testing.
In the current study, we observed continued high use 
of prasugrel or ticagrelor in CYP2C19 PMs, who have 
significantly limited capacity to activate clopidogrel. 
However, in line with a genotype-guided de-escalation 
approach, use of alternative antiplatelet therapy declined 
significantly over the 6  month period after PCI among 
those without a nonfunctional allele. Interestingly, there 
was a similar decline in IMs. The preference for continu-
ing alternative therapy in PMs, but not necessarily in 
IMs, could be based on the boxed warning on the FDA-
approved clopidogrel labeling, which is specific to PMs 
[30]. Data from the pragmatic study described above 
showing improved outcomes in IMs treatment with alter-
native therapy versus clopidogrel support continuation of 
alternative therapy in IMs [29]. However, these data were 
not available during the first year of implementation at 
UF Health Jacksonville. Of note, a limitation of our find-
ings is that we did not specifically assess whether factors, 
other than genotype, contributed to decisions to switch 
antiplatelet therapy, such as patient ability to afford alter-
native agents and presence of conditions that increase 
bleeding risk (e.g., use of concomitant oral anticoagu-
lants, frailty, and history of intracranial or other serious 
bleeding), nor did we collect data on loading doses or on 
patients not undergoing genotyping for comparison.
An additional lesson learned was the importance of 
clinical pharmacy support and electronic clinical deci-
sion support when there are delays in obtaining genotype 
results to assist with communicating results to provid-
ers after the patient has left the cardiac catheteriza-
tion laboratory and in some cases, after the patients has 
been discharged from the hospital. In settings where 
rapid genotyping is available and initial use of alterna-
tive therapy post PCI is high, one could argue that phar-
macist support may not be necessary to assist with early 
antiplatelet treatment decisions. Nonetheless, approxi-
mately 40% of IMs in the current study were placed on 
clopidogrel acutely, which is inconsistent with CPIC 
guidelines, suggesting that clinical pharmacist support 
and/or electronic clinical decision support may be war-
ranted regardless of genotype turnaround time. Phar-
macist support and electronic decision support may also 
be important in the chronic management of patients to 
assist genotype-guided decisions to de-escalate antiplate-
let therapy to clopidogrel. Indeed, at UF Health, Gaines-
ville, where there is significant pharmacist support plus 
electronic decision support, the majority of IMs were 
switched from clopidogrel to prasugrel or ticagrelor, 
consistent with CPIC recommendations. However, the 
opposite occurred in the absence of such support at UF 
Health, Jacksonville. Pharmacists can also play important 
roles in educating providers and patients on genetic test 
results and implications for treatment response regard-
less of genetic testing procedures.
Conclusion
Our data show that providing genotype-guided anti-
platelet therapy after PCI with the use of a rapid geno-
typing platform is feasible with high provider acceptance 
of genetic testing. This is among the first reports of 
implementation metrics with clinical use of a rapid 
CYP2C19 genotyping platform and the largest study of 
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rapid CYP2C19 genotyping in clinical care to date. With 
increasing use of newer antiplatelet agents, especially in 
the setting of ACS, our data suggest that genotyping may 
have an important role in informing maintenance anti-
platelet therapy following the early post-PCI period when 
risk for adverse events is highest.
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